Clinical Trial Results:
A Phase 2, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients with Relapsed or Refractory Hodgkin Lymphoma
Summary
|
|
EudraCT number |
2018-002556-32 |
Trial protocol |
DE BE PL FR CZ HU ES GB IT |
Global end of trial date |
19 Jan 2023
|
Results information
|
|
Results version number |
v2(current) |
This version publication date |
22 Mar 2024
|
First version publication date |
01 Feb 2024
|
Other versions |
v1 |
Version creation reason |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
ADCT-301-201
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT04052997 | ||
WHO universal trial number (UTN) |
- | ||
Other trial identifiers |
IND number: 121912 | ||
Sponsors
|
|||
Sponsor organisation name |
ADC Therapeutics SA
|
||
Sponsor organisation address |
Route de la Corniche, 3B, Epalinges, Switzerland, 1066
|
||
Public contact |
Clinical Trials Information, ADC Therapeutics SA, clinicaltrials@adctherapeutics.com
|
||
Scientific contact |
Clinical Trials Information, ADC Therapeutics SA, clinicaltrials@adctherapeutics.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
19 Jan 2023
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
19 Jan 2023
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
Evaluate the efficacy of single agent camidanlumab tesirine in participants with relapsed or refractory Hodgkin Lymphoma.
|
||
Protection of trial subjects |
Before initiating the study, an Investigator was required to have written and dated approval from the appropriate Institutional Review Board (IRB)/Independent Ethics Committee (IEC) for the study protocol, (i.e., a review panel responsible for ensuring the protection of the rights, safety, and well being of human participants involved in a clinical investigation, which was adequately constituted to provide assurance of that protection) according to local regulations. The IECs/IRBs were transparent in their functioning, independent of the researcher, the Sponsor, and any other undue influence, and duly qualified. All protocol amendments were reviewed and approved as required according to local regulations, prior to implementation. Other study documents subject to review during the study, including, but not limited to, serious adverse event (SAE) reports and other safety reports, were also submitted to the IEC/IRB.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
13 Sep 2019
|
||
Long term follow-up planned |
Yes
|
||
Long term follow-up rationale |
Safety, Efficacy | ||
Long term follow-up duration |
3 Years | ||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Canada: 6
|
||
Country: Number of subjects enrolled |
United States: 50
|
||
Country: Number of subjects enrolled |
Spain: 8
|
||
Country: Number of subjects enrolled |
United Kingdom: 13
|
||
Country: Number of subjects enrolled |
Belgium: 2
|
||
Country: Number of subjects enrolled |
Czechia: 3
|
||
Country: Number of subjects enrolled |
France: 5
|
||
Country: Number of subjects enrolled |
Hungary: 3
|
||
Country: Number of subjects enrolled |
Italy: 27
|
||
Worldwide total number of subjects |
117
|
||
EEA total number of subjects |
48
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
99
|
||
From 65 to 84 years |
17
|
||
85 years and over |
1
|
|
|||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||
Recruitment details |
Participants were enrolled from September 2019 to January 2023 across 9 countries (USA, Canada, Belgium, Czech Republic, France, Hungary, Italy, Spain, UK). | ||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||
Screening details |
Participants with relapsed or refractory Hodgkin Lymphoma received intravenous (IV) infusions of camidanlumab tesirine. | ||||||||||||||||||||
Period 1
|
|||||||||||||||||||||
Period 1 title |
Overall Study (overall period)
|
||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||
Allocation method |
Not applicable
|
||||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||||
Arms
|
|||||||||||||||||||||
Arm title
|
Camidanlumab Tesirine | ||||||||||||||||||||
Arm description |
Participants received IV infusions of camidanlumab tesirine every 3 weeks (Q3W) at a dose of 45 μg/kg on Day 1 of each cycle (one cycle = 21 days) for 2 cycles, followed by 30 μg/kg for subsequent cycles. | ||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||
Investigational medicinal product name |
Camidanlumab Tesirine
|
||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||
Other name |
ADCT-301
|
||||||||||||||||||||
Pharmaceutical forms |
Infusion
|
||||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||||
Dosage and administration details |
IV Infusion.
|
||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Camidanlumab Tesirine
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants received IV infusions of camidanlumab tesirine every 3 weeks (Q3W) at a dose of 45 μg/kg on Day 1 of each cycle (one cycle = 21 days) for 2 cycles, followed by 30 μg/kg for subsequent cycles. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Camidanlumab Tesirine
|
||
Reporting group description |
Participants received IV infusions of camidanlumab tesirine every 3 weeks (Q3W) at a dose of 45 μg/kg on Day 1 of each cycle (one cycle = 21 days) for 2 cycles, followed by 30 μg/kg for subsequent cycles. |
|
|||||||
End point title |
Overall Response Rate (ORR) [1] | ||||||
End point description |
ORR according to the 2014 Lugano classification as determined by central review in all-treated participants. ORR will be defined as the proportion of participants with a best overall response (BOR) of complete response (CR) or partial response (PR). All-Treated Population: All participants who received at least 1 dose of camidanlumab tesirine. This population was used in the primary analyses of efficacy and safety.
|
||||||
End point type |
Primary
|
||||||
End point timeframe |
Up to 3 years
|
||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No additional statistical analyses were pre-specified for this endpoint. |
|||||||
|
|||||||
No statistical analyses for this end point |
|
|||||||
End point title |
CR Rate | ||||||
End point description |
CR rate defined as the number of treated participants with a best overall response (BOR) of CR. All-Treated Population: All participants who received at least 1 dose of camidanlumab tesirine. This population was used in the primary analyses of efficacy and safety.
|
||||||
End point type |
Secondary
|
||||||
End point timeframe |
Up to 3 years
|
||||||
|
|||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Relapse-Free Survival (RFS) | ||||||||
End point description |
RFS defined as the time from the documentation of CR to disease progression or death. Data from participants in the All-Treated Population who achieved CR. Values of "99999" indicate the upper confidence interval was not reached due to lack of events.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Up to 3 years
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Progression-Free Survival (PFS) | ||||||||
End point description |
PFS defined as the time from first dose of study drug until the first date of either disease progression or death due to any cause. All-Treated Population: All participants who received at least 1 dose of camidanlumab tesirine. This population was used in the primary analyses of efficacy and safety.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Up to 3 years
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Duration of Response (DOR) | ||||||||
End point description |
DOR defined as the time from the first documentation of tumor response to disease progression or death. Data from participants in the All-Treated Population who achieved ether CR or PR by independent reviewer.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Up to 3 years
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Overall Survival (OS) | ||||||||
End point description |
OS defined as the time from first dose of study drug until death due to any cause. All-Treated Population: All participants who received at least 1 dose of camidanlumab tesirine. This population was used in the primary analyses of efficacy and safety. Values of "99999" indicate median and confidence intervals were not reached due to lack of events.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Up to 3 years
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||
End point title |
Number of Participants Who Experienced At Least One Treatment-emergent Adverse Event (TEAE) | ||||||
End point description |
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation where participants are administered a pharmaceutical product, which does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an AE that occurs or worsens in the period extending from the first dose of study drug to 30 days after the last dose of study drug in this study or start of a new anticancer therapy/procedure, whichever comes earlier. Clinically significant changes in vital signs, clinical laboratory results, and electrocardiogram were reported as AEs. All-Treated Population: All participants who received at least 1 dose of camidanlumab tesirine. This population was used in the primary analyses of efficacy and safety.
|
||||||
End point type |
Secondary
|
||||||
End point timeframe |
Up to 3 years
|
||||||
|
|||||||
No statistical analyses for this end point |
|
|||||||
End point title |
Number of Participants Who Experienced At Least One Serious Adverse Event (SAE) | ||||||
End point description |
An SAE is defined as any adverse event (AE) that:
• results in death
• is life threatening
• requires inpatient hospitalization or prolongation of existing hospitalization (hospitalization for elective procedures or for protocol compliance is not considered an SAE)
• results in persistent or significant disability/incapacity
• is a congenital anomaly/birth defect
• important medical events that do not meet the preceding criteria but based on appropriate medical judgement may jeopardize the participant or may require medical or surgical intervention to prevent any of the outcomes listed above.
Clinically significant changes in vital signs, clinical laboratory results, and electrocardiogram were reported as AEs. All-Treated Population: All participants who received at least 1 dose of camidanlumab tesirine. This population was used in the primary analyses of efficacy and safety.
|
||||||
End point type |
Secondary
|
||||||
End point timeframe |
Up to 3 years
|
||||||
|
|||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Number of Participants with ECOG Performance Status Score of 0-3 at the End of Trial (EOT) | ||||||||||||||
End point description |
The ECOG Performance Status is a scale used to asses a person's level of functioning in terms of their ability to care for themselves, daily activity, and physical ability. The scale consists of 6 grades, ranging from 0 to 5. A grade of 0 indicates the person is fully active and able to carry on as normal, and a grade of 5 indicates death. All-Treated Population: All participants who received at least 1 dose of camidanlumab tesirine and reported ECOG data at EOT. This population was used in the primary analyses of efficacy and safety.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
EoT (up to 3 years)
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||
End point title |
Number of Participants Who Received Hematopoietic Stem Cell Transplant (HSCT) | ||||||
End point description |
Participants receiving HSCT following camidanlumab tesirine, and without any other anticancer therapy in between, other than the therapies preparing for HSCT, were included in this analysis. All-Treated Population: All participants who received at least 1 dose of camidanlumab tesirine. This population was used in the primary analyses of efficacy and safety.
|
||||||
End point type |
Secondary
|
||||||
End point timeframe |
Up to 3 years
|
||||||
|
|||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Maximum Observed Plasma Concentration (Cmax) of Camidanlumab Tesirine Total Antibody, PBD-Conjugated Antibody, and Unconjugated Warhead SG3199 | ||||||||||||||||||||
End point description |
PK Population: The analysis only included participants who received study drug and had at least 1 pre-Cycle 1 Day 1 and 1 post-dose valid (measurable) assessment. Due to the nature of the studied drug (antibody-drug conjugate), some PK parameters frequently could not be measured, or could be measured only briefly.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Cycle 1 (one cycle = 21 days): day 1 (predose, EOI, 4h postdose), day 8 (168h), day 15 (336h). Cycle 2: day 1 (predose, EOI, 4h postdose), day 8 (168h), day 15 (336h)
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Area Under the Plasma Concentration-Time Curve From Time 0 to the End of the Dosing Interval (AUCtau) For Camidanlumab Tesirine Total Antibody, PBD-Conjugated Antibody, and Unconjugated Warhead SG3199 | ||||||||||||||
End point description |
PK Population: The analysis only included participants who received study drug and had at least 1 pre-Cycle 1 Day 1 and 1 post-dose valid (measurable) assessment. Due to the nature of the studied drug (antibody-drug conjugate), some PK parameters frequently could not be measured, or could be measured only briefly.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Cycle 2 (one cycle = 21 days): day 1 (predose, EOI, 4h postdose), day 8 (168h), day 15 (336h)
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) For Camidanlumab Tesirine Total Antibody, PBD-Conjugated Antibody, and Unconjugated Warhead SG3199 | ||||||||||||||||||||
End point description |
PK Population: The analysis only included participants who received study drug and had at least 1 pre-Cycle 1 Day 1 and 1 post-dose valid (measurable) assessment. Due to the nature of the studied drug (antibody-drug conjugate), some PK parameters frequently could not be measured, or could be measured only briefly.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Cycle 1 (one cycle = 21 days): day 1 (predose, EOI, 4h postdose), day 8 (168h), day 15 (336h). Cycle 2: day 1
(predose, EOI, 4h postdose), day 8 (168h), day 15 (336h)
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUCinf) For Camidanlumab Tesirine Total Antibody, PBD-Conjugated Antibody, and Unconjugated Warhead SG3199 | ||||||||||||||
End point description |
PK Population: The analysis only included participants who received study drug and had at least 1 pre-Cycle 1 Day 1 and 1 post-dose valid (measurable) assessment. Due to the nature of the studied drug (antibody-drug conjugate), some PK parameters frequently could not be measured, or could be measured only briefly. Values of "99999" indicate that the geometric mean and coefficient of variation were not quantifiable due to the low level of observations.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Cycle 1 (one cycle = 21 days): day 1 (predose, EOI, 4h postdose), day 8 (168h), day 15 (336h)
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Clearance (CL) For Camidanlumab Tesirine Total Antibody, PBD-Conjugated Antibody, and Unconjugated Warhead SG3199 | ||||||||||||||
End point description |
PK Population: The analysis only included participants who received study drug and had at least 1 pre-Cycle 1 Day 1 and 1 post-dose valid (measurable) assessment. Due to the nature of the studied drug (antibody-drug conjugate), some PK parameters frequently could not be measured, or could be measured only briefly. Values of "99999" indicate that the geometric mean and coefficient of variation were not quantifiable due to the low level of observations.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Cycle 1 (one cycle = 21 days): day 1 (predose, EOI, 4h postdose), day 8 (168h), day 15 (336h)
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Clearance at Steady State (CLss) For Camidanlumab Tesirine Total Antibody, PBD-Conjugated Antibody, and Unconjugated Warhead SG3199 | ||||||||||||||
End point description |
PK Population: The analysis only included participants who received study drug and had at least 1 pre-Cycle 1 Day 1 and 1 post-dose valid (measurable) assessment. Due to the nature of the studied drug (antibody-drug conjugate), some PK parameters frequently could not be measured, or could be measured only briefly. Values of "99999" indicate that the geometric mean and coefficient of variation were not quantifiable due to the low level of observations.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Cycle 2 (one cycle = 21 days): day 1 (predose, EOI, 4h postdose), day 8 (168h), day 15 (336h)
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Apparent Terminal Elimination Half-Life (T1/2) For Camidanlumab Tesirine Total Antibody, PBD-Conjugated Antibody, and Unconjugated Warhead SG3199 | ||||||||||||||||||||
End point description |
PK Population: The analysis only included participants who received study drug and had at least 1 pre-Cycle 1 Day 1 and 1 post-dose valid (measurable) assessment. Due to the nature of the studied drug (antibody-drug conjugate), some PK parameters frequently could not be measured, or could be measured only briefly. Values of "99999" indicate that the geometric mean and coefficient of variation were not quantifiable due to the low level of observations.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Cycle 1 (one cycle = 21 days): day 1 (predose, EOI, 4h postdose), day 8 (168h), day 15 (336h). Cycle 2: day 1 (predose, EOI, 4h postdose), day 8 (168h), day 15 (336h)
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Volume of Distribution at Steady State (Vss) For Camidanlumab Tesirine Total Antibody, PBD-Conjugated Antibody, and Unconjugated Warhead SG3199 | ||||||||||||||||||||
End point description |
PK Population: The analysis only included participants who received study drug and had at least 1 pre-Cycle 1 Day 1 and 1 post-dose valid (measurable) assessment. Due to the nature of the studied drug (antibody-drug conjugate), some PK parameters frequently could not be measured, or could be measured only briefly. Values of "99999" indicate that the geometric mean and coefficient of variation were not quantifiable due to the low level of observations.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Cycle 1 (one cycle = 21 days): day 1 (predose, EOI, 4h postdose), day 8 (168h), day 15 (336h). Cycle 2: day 1 (predose, EOI, 4h postdose), day 8 (168h), day 15 (336h)
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Accumulation Index (AI) For Camidanlumab Tesirine Total Antibody, PBD-Conjugated Antibody, and Unconjugated Warhead SG3199 | ||||||||||||||
End point description |
AI is the ratio of area under the serum concentration-time curve (AUC) from 0 to 21 days for Cycle 2 divided by AUC from 0 to 21 days for Cycle 1. PK Population: The analysis only included participants who received study drug and had at least 1 pre-Cycle 1 Day 1 and 1 post-dose valid (measurable) assessment. Due to the nature of the studied drug (antibody-drug conjugate), some PK parameters frequently could not be measured, or could be measured only briefly. Values of "99999" indicate that the geometric mean and coefficient of variation were not quantifiable due to the low level of observations.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Cycle 1 and 2: day 0 to 21
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||
End point title |
Number of Participants With Confirmed Positive Anti-Drug Antibody (ADA) Responses Post Dose | ||||||
End point description |
Detection of ADAs was performed by using a screening assay for identification of antibody positive samples/participants, a confirmation assay, and titer assessment. All-Treated Population: All participants who received at least 1 dose of camidanlumab tesirine. This population was used in the primary analyses of efficacy and safety.
|
||||||
End point type |
Secondary
|
||||||
End point timeframe |
Up to 3 years
|
||||||
|
|||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||
End point title |
Change From Baseline in Health-Related Quality of Life (HRQoL) as Measured by EuroQoL-5 Dimensions-5 Levels (EQ-5D-5L) Visual Analog Scale (VAS) | ||||||||||||||||||||||||||||||||||||||
End point description |
Participants were asked to indicate their health state on a VAS with scores ranging from ‘the worst health you can imagine’ (score 0) to 'the best health you can imagine’ (score 100). Participants are asked to mark an “X” on the VAS to indicate their own health and then to report the score in a text box. Positive changes from Baseline represent an an improvement in heath. Patient Reported Outcome (PRO) Population: All participants in the all-treated patients with baseline score (at least one instrument) and at least 1 post-baseline score (in at least one instrument).
|
||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||
End point timeframe |
Baseline, Day 1 of Cycles 2 to 15 (one cycle = 21 days) and EOT (up to 3 years)
|
||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||
End point title |
Change From Baseline in HRQoL as Measured by Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) | ||||||||||||||||||||||||||||||||||||||
End point description |
The FACT-Lym consists of a 27-item general core questionnaire (i.e., Functional Assessment of Cancer Therapy - General [FACT-G]) and a 15-item disease-specific questionnaire (Lymphoma Subscale). The FACT-G includes 4 domains: physical well-being, social/family well-being, emotional well-being, and functional well-being. The total FACT Lym score (0-168) was obtained by summing individual subscale scores. Higher scores for the scales indicate better quality of life. Change was calculated as the value at the last observation minus the value at baseline. PRO Population: All participants in the all-treated patients with baseline score (at least one instrument) and at least 1 post-baseline score (in at least one instrument).
|
||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||
End point timeframe |
Baseline, Day 1 of Cycles 2 to 15 (one cycle = 21 days) and EOT (up to 3 years)
|
||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Up to 3 years
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
All AEs, AESIs, and SAEs regardless of relationship to study drug were reported from the time a participant signed the ICF until 30 days after the last dose of study drug. After 30 days following the last dose of study drug, only related SAEs were reported.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
22.0.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Camidanlumab Tesirine
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
All participants received IV infusions of camidanlumab tesirine Q3W at a dose of 45 μg/kg on Day 1 of each cycle (one cycle = 21 days) for 2 cycles, followed by 30 μg/kg for subsequent cycles. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||
Substantial protocol amendments (globally) |
|||||||
Were there any global substantial amendments to the protocol? Yes | |||||||
Date |
Amendment |
||||||
24 Jun 2019 |
The primary reason for Protocol Amendment 1 was to include changes based on recommendations by the United States (US) Food and Drug Administration (FDA). In addition, substantial updates in line with study needs had been introduced, e.g., revision of study drug instructions or clarifications of male participant contraception methods. |
||||||
24 Apr 2020 |
The primary reason for this global Protocol Amendment 2 was to combine the updates required by the Regulatory Authorities and IRB/IEC received to date in one global protocol version. In addition, updates in line with study needs had been introduced, such as the inclusion of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) added to the list of pathogens associated to Guillain-Barré syndrome (GBS), additional recommendation to capture early signs of polyradiculopathy/GBS, and the update of the study stopping rule. |
||||||
01 Jul 2020 |
The primary reason for this global Protocol Amendment 3 was to update the stopping rule and to exclude participants that are tested positive for influenza and SARS-CoV-2 before initiating study treatment, based on the recommendations by the FDA. |
||||||
06 Nov 2020 |
The primary reasons for this global Protocol Amendment 4 were to implement the recommendations from the independent Data and Safety Monitoring Board (iDSMB), including the addition of varicella zoster virus prophylaxis, an update of the management guidance in respect to specific autoimmune toxicities, and to address the requests from the French and Belgian regulatory authorities. |
||||||
16 Feb 2022 |
The primary reason for Protocol Amendment 5 is to extend the contraception period after last dose of camidanlumab tesirine, following an urgent safety measure. The contraception period is determined based on the compound properties and half-life, and has been updated due to a recently revised half-life value of camidanlumab tesirine. |
||||||
Interruptions (globally) |
|||||||
Were there any global interruptions to the trial? Yes | |||||||
|
|||||||
Limitations and caveats |
|||||||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||||||
None reported |